Stock Market Reviews

VTYX (Ventyx Biosciences, Inc.) News

Get the latest news, insights, and market updates on VTYX (Ventyx Biosciences, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Analysts Bullish as Ventyx Biosciences (VTYX) Advances Its Clinical and Strategic Initiatives
  With strong 1-year returns and upside potential, Ventyx Biosciences, Inc. (NASDAQ:VTYX) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026. As of December 18, 2025, 90% of analysts are bullish on Ventyx Biosciences, Inc. (NASDAQ:VTYX), setting a median price target of $14.00. This translates into a massive […]
  Dec 21, 2025 - $VTYX
• Ventyx Provides Clinical and Corporate Updates
  Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development planInterim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyx’s R&D Day planned for Q1 2026 SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq
  Dec 2, 2025 - $VTYX
• Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference
  SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York. Piper Sandler 37th Annual Healthcare Conference details:Fires
  Dec 1, 2025 - $VTYX
• With 57% ownership, Ventyx Biosciences, Inc. (NASDAQ:VTYX) boasts of strong institutional backing
  Key Insights Institutions' substantial holdings in Ventyx Biosciences implies that they have significant influence over...
  Nov 24, 2025 - $VTYX
• Ventyx Biosciences (VTYX) Outlook Strengthened by Cost Optimization and Positive Clinical Data
  Ventyx Biosciences Inc. (NASDAQ:VTYX) is among the hottest SMID-cap stocks so far in 2025. On November 7, TheFly reported that Canaccord Genuity modestly increased its price target on the company’s stock from $14 to $16 while reiterating a Buy rating following the company’s Q3 results report a day earlier. Canaccord is now factoring in lower operating […]
  Nov 23, 2025 - $VTYX
• Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London
  SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London. Jefferies Global Healthcare Conference details:Fireside ChatDate: Wednes
  Nov 17, 2025 - $VTYX
• Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress
  Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a biomarker trial support the potential use of VTX3232 as a disease-modifying therapy for patients with Parkinson’s diseaseTopline data from Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025Cash, cash equivalents and marketable securities balance of $192.6M as of September
  Nov 6, 2025 - $VTYX
• Ventyx Biosciences (VTYX): Assessing Valuation After Breakthrough Phase 2 Results for VTX3232
  Ventyx Biosciences (VTYX) gained investor attention this week after reporting impressive Phase 2 trial results for its oral therapy VTX3232. The study found VTX3232 reduced key inflammation markers in patients with obesity and cardiovascular risk factors. See our latest analysis for Ventyx Biosciences. Following the positive Phase 2 data, Ventyx Biosciences has seen significant gains, with the latest share price return up 95% over the past month and a remarkable 172% gain year-to-date...
  Oct 27, 2025 - $VTYX
• Ventyx Biosciences (VTYX) Rethinks Anti-Inflammatory Pipeline After Promising Phase 2 Results for VTX3232
  Ventyx Biosciences recently announced positive topline results from its Phase 2 trial of VTX3232, showing significant reductions in key inflammatory biomarkers such as hsCRP, IL-6, and Lp(a) in patients with obesity and cardiovascular risk factors. These findings highlight the potential of VTX3232 as an oral, once-daily anti-inflammatory therapy, both as a monotherapy and in combination with established GLP-1 treatments like semaglutide. We'll explore how the substantial reduction in...
  Oct 26, 2025 - $VTYX
• Ventyx Biosciences Reports Positive Phase 2 Data for Oral NLRP3 Inhibitor VTX3232 in Obesity and Cardiovascular Risk
  Ventyx Biosciences Inc. (NASDAQ:VTYX) is one of the best NASDAQ stocks under $5 to buy now. On October 22, Ventyx Biosciences announced positive topline results from its Phase 2 study of the oral, once-daily drug VTX3232 in 175 participants with obesity and cardiovascular risk factors. The study was a randomized, double-blind, placebo-controlled, multicenter trial that […]
  Oct 26, 2025 - $VTYX